No Dose Reduction Required for Rosuvastatin at eGFR 55
Rosuvastatin does not require dose reduction for a patient with an eGFR of 55 mL/min/1.73 m², as dose adjustment is only recommended when eGFR falls below 30 mL/min/1.73 m².
FDA-Approved Dosing Guidelines
The FDA prescribing information for rosuvastatin is clear and definitive 1:
- No dose adjustment is necessary for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²)
- Dose reduction is only required for severe renal impairment (eGFR <30 mL/min/1.73 m²):
- Start at 5 mg daily
- Maximum dose should not exceed 10 mg daily
Your patient with an eGFR of 55 mL/min/1.73 m² falls into the CKD Stage 3a category (mild to moderate impairment), where standard rosuvastatin dosing (5-40 mg daily) can be safely used without modification.
Supporting Guideline Evidence
The KDOQI guidelines 2 specifically address statin dosing in CKD and note that statins show "no increase in toxicity for simvastatin dosed at 20 mg per day or simvastatin 20 mg/ezetimibe 10 mg combinations per day in people with GFR < 30 ml/min/1.73 m²." While these guidelines suggest avoiding high-intensity statins in patients with eGFR <60 mL/min/1.73 m² 3, this recommendation is based on the doses used in CKD trials rather than documented toxicity, and does not mandate dose reduction—only consideration of moderate-intensity rather than high-intensity regimens.
The 2007 KDOQI guidelines 4 explicitly state for rosuvastatin: "No dose modification necessary for patients with mild to moderate kidney disease. CCr < 30 mL/min/1.73 m², not on hemodialysis, initiate dosing at 5 mg daily and do not exceed 10 mg daily."
Clinical Evidence on Safety
Multiple studies support the safety of rosuvastatin at standard doses in patients with eGFR >30 mL/min/1.73 m²:
- A comprehensive analysis of 40,600 participants found no increased risk of renal impairment or renal failure with rosuvastatin compared to placebo, even in patients with baseline eGFR <60 mL/min/1.73 m² 5
- Short-term rosuvastatin treatment actually increased eGFR by 0.8-3.2 mL/min/1.73 m² in patients across all renal function categories 6
- In HIV patients with CKD and eGFR 50-60 mL/min/1.73 m², rosuvastatin 10 mg daily showed renal protective effects with minimal eGFR decline 7
Important Caveats
While dose reduction is not required at eGFR 55, be aware of:
Dose-dependent proteinuria risk: Higher rosuvastatin doses (20-40 mg) are associated with increased urinary protein excretion 8. A 2022 study found that 44% of patients with eGFR <30 mL/min/1.73 m² inappropriately received high-dose rosuvastatin (20-40 mg), which was associated with increased hematuria, proteinuria, and kidney failure risk 9
Monitor for progression: If eGFR declines to <30 mL/min/1.73 m², then reduce to maximum 10 mg daily per FDA labeling 1
Myopathy risk: All patients with any degree of renal impairment have increased myopathy risk and should be monitored accordingly 1
Consider moderate-intensity dosing: While not mandatory, the KDIGO approach suggests using moderate-intensity statin regimens (rosuvastatin 5-10 mg) rather than high-intensity (20-40 mg) in patients with eGFR <60 mL/min/1.73 m² 3, 10
Practical Recommendation
For your patient with eGFR 55 mL/min/1.73 m²:
- Continue or initiate rosuvastatin at standard doses (typically 10-20 mg daily for most indications)
- No dose reduction is required based on renal function alone
- Monitor renal function every 6-12 months
- Reduce dose to ≤10 mg daily only if eGFR falls below 30 mL/min/1.73 m²
- Consider baseline and periodic monitoring for proteinuria if using higher doses (≥20 mg)